Joby Aviation stock keeps rising on news that it will ‘explore opportunities' to supply flying taxis to Saudi Arabia
Shares in Joby Aviation (NYSE: JOBY) jumped yesterday after the air taxi company announced a potential deal with the Saudi Arabia-based Abdul Latif Jameel. The deal could lead to Joby supplying up to 200 of its eVTOL aircraft. Here's what to know about the potential and its effect on Joby's stock price.
The household auto fleet is a money pit
Why AI Is Making 1:1 Meetings Irrelevant
Where are the wildfires in Canada? Maps pinpoint the location of fires and air-quality threats from smoke
Joby Aviation, better known as Joby, is a Santa Cruz, California-headquartered aviation company that is developing a fleet of electric vertical takeoff and landing (eVTOL) vehicles—in other words, flying taxis.
Joby was founded in 2009 and went public on the New York Stock Exchange in 2021 via a special purpose acquisition company, or SPAC. Prior to its NYSE debut, Joby was named one of Fast Company's Most Innovative Companies for 2021.
While the company is developing flying taxi vehicles, one of its primary aims is to become a service—an Uber of the skies, so to speak.
Because of its relatively small market cap of around $6.7 billion and interesting futuristic product (a flying rideshare service), Joby's stock is somewhat popular with investors who lean more toward dabbling in meme stocks and small-cap stocks that have potential to see sky-high returns if their products eventually take off (no pun intended).
Joby says it currently has 'strategic partnerships' with Toyota, Delta, and Uber, and it employs more than 1,700 engineers. For its Q1 2025, which ended March 31, Joby reported a net loss of $82.4 million.
Yesterday, Joby Aviation announced a potential deal with Abdul Latif Jameel, a business based in Saudi Arabia.
Potential is the key word here.
That's because the two companies didn't actually agree to sell anything to or buy anything from one another. Instead, they signed a Memorandum of Understanding (MoU). This MoU will see the companies 'explore opportunities to establish a distribution agreement in Saudi Arabia for Joby's electric aircraft,' according to Joby.
That potential distribution agreement may see Joby deliver up to 200 air taxis and other related services valued at up to $1 billion to Abdul Latif Jameel 'over the coming years.'
Joby has positioned the potential deal as a win-win for both American and Saudi Arabian business interests.
'This collaboration is about bringing America's leadership in electric air mobility to the world,' Joby Aviation CEO JoeBen Bevirt said in a statement announcing the deal.
Given that Joby has recently been worth about $6 billion in total, it's no wonder the company's stock jumped yesterday after it announced it was exploring a single deal worth up to $1 billion. By the close of the market yesterday, JOBY stock had risen over 7% to $8.03 per share.
In premarket trading this morning, as of the time of this writing, JOBY stock is up another 2%.
However, while JOBY stock has been flying high over the past two days, it's important to put the stock's past performance into perspective. Despite JOBY's stock price surge in the last 24 hours, the company's stock was still down year-to-date by 1.23% as of yesterday's close.
At the same time, when you look at the last 12 months, JOBY shares have had a significant return. Since last June, the stock has risen nearly 65%.
Where the stock goes from here is anyone's guess. However, the company has had some exciting advances in recent years.
In February 2024, Joby announced that it plans to launch an air taxi service in Dubai by 2026, and in October 2024, Joby showed off one of its air taxis to much fanfare in New York's Grand Central Station.
The company said that an air taxi could carry up to 1,000 pounds of payload/people, had a range of 100 miles, and could reach speeds up to 200 mph.
This post originally appeared at fastcompany.comSubscribe to get the Fast Company newsletter: http://fastcompany.com/newsletters
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
Strong cash position of CHF2.8 million at end of Q1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studies Entered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 19, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2025 financial results and provided a corporate update. 'We have had a great start to 2025 both in terms of product development and achieving business milestones. Progress continues well and on track with our GABAB PAM drug candidate in chronic cough. Positive data from this program in multiple preclinical models was recently presented at the prestigious American cough conference. We have also regained rights to our Phase 2 mGlu2 PAM asset, ADX71149,' said Tim Dyer, CEO of Addex. 'Solidifying our position to use mGlu5 NAMs in brain injury, we entered an option agreement with Sinntaxis to gain access to additional intellectual property. Our plan is to explore further the clinical activity of dipraglurant in this indication. Finally, our partner, Indivior, indicated that they have advanced their GABAB PAM clinical candidate through IND enabling studies, providing additional validation of our allosteric modulation approach.' Operating Highlights: GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in multiple models of disease Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced their GABAB PAM program for substance use disorders successfully through IND enabling studies Entered option agreement with Sinntaxis for exclusive license to intellectual property covering use of mGlu5 NAM in brain injury recovery Key Q1 2025 Financial Data CHF' thousands Q1 2025 Q1 2024 Change Income 71 235 (164) R&D expenses (156) (245) 89 G&A expenses (521) (778) 257 Total operating loss (606) (788) 182 Finance result, net (19) 53 (72) Share of net loss of associates (848) - (848) Net loss from continuing operations (1,473) (735) (738) Net loss from discontinued operations - (2,352) 2352 Net loss for the period (1,473) (3,087) 1,614 Basic and diluted net loss per share:From continuing operations (0.01) (0.01) - From discontinued operations - (0.02) (0.02) Total basic and diluted net loss per share (0.01) (0.03) (0.02) Net decrease in cash during the period (517) (2,237) 1,720 Cash and cash equivalents 2,825 1,628 1,197 Shareholders' equity 8,296 (1,373) 9,669 Financial Summary:Income decreased by CHF 0.2 million during the three-month period ended March 31, 2025 compared to the same period ended March 31, 2024, primarily due to the completion of the service agreement with Indivior on June 30, 2024. R&D expenses decreased by CHF 0.1 million during three-month period ended March 31, 2025 compared to the same period ended March 31, 2024 primarily due to lower GABAB PAM outsourced R&D expenses as we successfully completed the research phase of our agreement with Indivior on June 30, 2024. G&A expenses decreased by CHF 0.3 million during the three-month period ended March 31, 2025 compared to the same period ended March 31, 2024 primarily due to reduced legal fees. Net loss decreased by CHF 1.6 million during the three-month period ended March 31, 2025 compared to the same period ended March 31, 2024, primarily due to the discontinued loss of CHF 2.4 million incurred during the three-month period ended March 31, 2024, related to activities divested on April 2, 2024, partially offset by the share of the net loss of Neurosterix Group incurred for CHF 0.9 million during the three-month period ended March 31, 2025. Basic and diluted loss per share amounted to CHF 0.01 per share for the three-month period ended March 31, 2025 compared to a basic and diluted loss per share of CHF 0.03 for the same period ended March 31, 2024. Cash and cash equivalents increased to CHF 2.8 million at March 31, 2025, compared to CHF 1.6 million at March 31, 2024. The increase of CHF 1.2 million between March 31, 2025 and March 31, 2024 is primarily due to the gross proceeds of CHF 5.0 million from the Neurosterix Transaction received in April 2024, partially offset by the cash used in operating activities. Q1 2025 Consolidated Financial Statements:The Q1 2025 financial report can be found on the Company's website in the investor/download section here. Conference Call Details:A conference call will be held today, June 19, 2025, at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) to review the financial results. Tim Dyer, Chief Executive Officer and Mikhail Kalinichev, Head of Translational Science will deliver a brief presentation followed by a Q&A session. Joining the Conference Call: Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN. In the 10 minutes prior to the call's start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number. Webcast registration URL: Conference call registration URL: About Addex Therapeutics Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@ Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@ Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
22 minutes ago
- Newsweek
Trump Lashes Out at 'Dummy' Jerome Powell As Pressure Tactics Ignored
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump called Federal Reserve Chair Jerome Powell "a real dummy" after interest rates were held steady once again. Trump has been sharply critical of Powell, publicly chastising him for not cutting interest rates sooner and making clear he wants a new Fed chair. "Too Late—Powell is the WORST. A real dummy, who's costing America $Billions!" Trump posted to his Truth Social platform. The Fed is concerned about the outlook for inflation, largely due to the uncertainty over tariffs and trade. Trump believes higher interest rates are holding back the American economy unnecessarily. This is a developing article. Updates to follow.
Yahoo
28 minutes ago
- Yahoo
Nippon Steel finalises US Steel takeover after state opposition
Nippon Steel and US Steel said on Wednesday they have finalised their 'historic partnership', a deal that gives the US government a say in some business matters and comes a year-and-a-half after the Japanese company first proposed its nearly $15bn (€13bn) buyout of the iconic American steelmaker. The pursuit by Nippon Steel of the Pittsburgh-based company was buffeted by national security concerns and presidential politics in a premier battleground state, dragging out the transaction for more than a year after US Steel shareholders approved it. It also forced Nippon Steel to expand the deal, including adding a so-called 'golden share' provision that gives the federal government the power to appoint a board member and have a say in company decisions that affect domestic steel production and competition with overseas producers. 'Together, Nippon Steel and US Steel will be a world-leading steelmaker, with best-in-class technologies and manufacturing capabilities,' the companies said. The combined company will become the world's fourth-largest steelmaker in an industry dominated by the Chinese, and bring what analysts say is Nippon Steel's top-notch technology to US Steel's antiquated steelmaking processes, plus a commitment to invest $11bn (€9.6bn) to upgrade US Steel facilities. In exchange, Nippon Steel gets access to a robust US steel market, strengthened in recent years by tariffs under President Donald Trump and former President Joe Biden, analysts say. Anthony Rapa, a Blank Rome lawyer in Washington who advises firms on trade, operations and investments, said the government's intervention in the Nippon Steel-US Steel deal is another sign of a trend that the US is increasingly equating economic security with national security. He doesn't see the government's intervention as chilling foreign investment and said that using a 'golden share' mechanism to ease national security concerns is unlikely to happen frequently — only in sensitive and complex cases. Still, the episode could cause investors to be more strategic in how they approach transactions, Rapa said. Anil Khurana, executive director of the Baratta Center for Global Business at Georgetown University, said the US government's interest in the deal is a sign of the growing importance it places on economic competition with China. 'Clearly the definition of what is national security has expanded to include national economic security, which is where I think this comes in,' Khurana said. Nippon Steel and US Steel did not release a copy of the national security agreement struck with Trump's administration. But in a statement on Wednesday, the companies said the federal government will have the right to appoint an independent director and get 'consent rights' on specific matters. Related US Steel and Nippon file lawsuit after Biden blocks merger deal President Trump orders review into Nippon Steel's bid for US Steel Those include reductions in Nippon Steel's capital commitments in the national security agreement; changing US Steel's name and headquarters; closing or idling US Steel's plants; transferring production or jobs outside of the US; buying competing businesses in the US; and certain decisions on trade, labour and sourcing outside the US. Nippon Steel announced in December 2023 that it planned to buy the steel producer for $14.9bn (€13bn) in cash and debt, and committed to keep the US Steel name and Pittsburgh headquarters. The United Steelworkers union, which represents some US Steel employees, opposed the deal, and Biden and Trump both vowed from the campaign trail to block it. Biden used his authority to block Nippon Steel's acquisition of US Steel on his way out of the White House after a review by the Committee on Foreign Investment in the United States. After he was elected, Trump changed course, expressing openness to working out an arrangement and ordering another review by the committee. That's when the idea of the 'golden share' emerged as a way to resolve national security concerns and protect American interests in domestic steel production. As it sought to win over American officials, Nippon Steel began adding commitments. Those included putting US Steel under a board made up of a majority of Americans and a management team of Americans. It pledged not to conduct layoffs or plant closings as a result of the transaction or to import steel slabs to compete with US Steel's blast furnaces in Braddock, Pennsylvania and Gary, Indiana. In the final agreement, it pledged to produce and supply US Steel from domestic sources — such as mining operations in Minnesota — and to allow US Steel to pursue trade actions under US law. It also made a series of bigger capital commitments in US Steel facilities, tallying $11bn (€9.6bn) through 2028, it said. Nippon Steel said its annual crude steel production capacity is expected to reach 86mn tons, closer to its goal of 100mn tons. The United Steelworkers on Wednesday noted that its current labour agreement with US Steel expires in 2026. "Rest assured, if our job security, pensions, retiree health care or other hard-earned benefits are threatened, we are ready to respond with the full strength and solidarity of our membership," its international president, David McCall, said in a statement. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
